Titan Pharmaceuticals, Inc.  

(Public, OTCMKTS:TTNP)   Watch this stock  
Find more results for ttnp
0.842
+0.032 (3.95%)
Jun 2 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.80 - 0.84
52 week 0.44 - 0.87
Open 0.81
Vol / Avg. 389,136.00/317,358.00
Mkt cap 89.37M
P/E     -
Div/yield     -
EPS -0.05
Shares 110.33M
Beta 1.75
Inst. own 6%
May 14, 2015
Q1 2015 Titan Pharmaceuticals Inc Earnings Call
May 13, 2015
Q1 2015 Titan Pharmaceuticals Inc Earnings Release
Apr 1, 2015
Q4 2014 Titan Pharmaceuticals Inc Earnings Call
Mar 31, 2015
Q4 2014 Titan Pharmaceuticals Inc Earnings Release
Mar 9, 2015
Titan Pharmaceuticals Inc at ROTH Conference
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -537.54% -65.91%
Operating margin -177.28% -95.31%
EBITD margin - -85.63%
Return on average assets -100.11% -12.24%
Return on average equity -306.86% -33.44%
Employees 13 -
CDP Score - -

Address

Suite 505, 400 Oyster Point Blvd
SAN FRANCISCO, CA 94080
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

Description

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Its product development programs focus primarily on important pharmaceutical markets with significant unmet medical needs and commercial potential. Its ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, around the clock blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. The Company’s products are Probuphine and Fanapt (iloperidone). Its Probuphine is specifically designed for the long-term treatment of opioid dependence and utilizes ProNeura, proprietary, long-term drug delivery technology. The Company’s Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia.

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 60
Sunil Ramraje Bhonsle President, Director
Age: 65
Joseph A. Akers Independent Director
Age: 69
Victor J. Bauer Ph.D. Independent Director
Age: 79
Eurelio M. Cavalier Independent Director
Age: 82
M. David David MacFarlane Ph.D. Independent Director
Age: 74
James R. McNab Jr. Independent Director
Age: 71